# US 2016/0354397 A1 · Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354397 A1
- Document ID: US20160354397A1
- Status: Published application
- Kind: A1
- Application number: 15/181,631
- Filed: 2016-06-14
- Published: 2016-12-08
- Earliest claimed: 2004-09-07
- Assignees: Pacific Arrow Limited
- Applicants: Pacific Arrow Limited
- Inventors: Pui-Kwong CHAN; May Sung MAK; Yun WANG
- Web page: https://patentgrep.com/patent/US20160354397A1

## CPC

- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/365: Lactones
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphatic cancer, pancreas cancer, stomach cancer and thyroid cancer.

## Claims

### Claim at position 1

1-142. (canceled)

### Claim 143

A compound for modulating the secretion or expression of adhesion proteins or angiopoietins of cells, for inhibiting the metastasis of cancer cell in a subject, comprising contacting said subject with an effective amount of an isolated, purified or synthesized compound, or its salt, or ester thereof, selected from the formula:
also named (1E),
wherein
R1 is selected from hydrogen, hydroxyl, O-angeloyl, O-tigloyl, O-senecioyl, O-alkyl, O-dibenzoyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-benzoyl alkyl substituted O-alkanoyl, O-alkanoyl substituted with phenyl, O-alkenoyl substituted with phenyl, O-aryl, O-acyl, O-heterocylic, O-heteroraryl, and derivatives thereof;
R2 is selected from hydrogen, hydroxyl, O-angeloyl, O-tigloyl, O-senecioyl, O-alkyl, O-dibenzoyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-benzoyl alkyl substituted O-alkanoyl, O-alkanoyl substituted phenyl, 0-alkenoylsubstituted phenyl, O-aryl, O-acyl, O-heterocylic, O-heteroraryl, and derivatives thereof;
R4 represents CH3, CHO, CH2R6 or COR6, wherein R6 is selected from hydroxyl, O-angeloyl, O-tigloyl, O-senecioyl, O-alkyl, O-dibenzoyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-benzoyl alkyl substituted O-alkanoyl, O-alkanoyl substituted phenyl, O-alkenoyl substituted phenyl, O-aryl, O-acyl, O-heterocylic, O-heteroraryl, and derivatives thereof; R3 is H or OH; R8 is H or OH;
R16 is H, or R4 and R16 may form an oxygen bridge with divalent radical formula of —CH2-O—, CH(OH)—O— or C(═O)—O—, wherein the —O-may be replaced with —NH—; wherein when the C12-13 of ring 3 of the triterpene has a double bond then R16 is absent;
R5 is a hydrogen, heterocyclic or sugar moiety(ies), wherein the sugar moiety(ies) is/are selected from a group consisting of glucose, galactose, rhamnose, arabinose, xylose, fucose, allose, altrose, gulose, idose, lyxose, mannose, psicose, ribose, sorbose, tagatose, talose, fructose, alduronic acid, glucuronic acid, galacturonic acid, and derivatives or combination thereof; wherein R9, R10, R11, R12, R13, R14, R15 are independently attached a group selecting from CH3, CH2OH, CHO, COOH, COO-alkyl, COO-aryl, COO-heterocyclic, COO-heteroaryl, CH2Oaryl, CH2O-heterocyclic, CH2O-heteroaryl, alkyls group, hydroxyl, acetyl group, particularly CH3; wherein at least two of R1, R2 and R6 are comprising a group selected from O-angeloyl, O-tigloyl, O-senecioyl, O-dibenzoyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-benzoyl alkyl substituted O-alkanoyl, O-aryl, O-acyl, O-heterocylic, O-heteroraryl, and derivatives thereof; or at least one of R1, R2, and R4 is a sugar moiety substituted with at least two groups selected from a group consisting of angeloyl, acetyl, tigloyl, senecioyl, benzoyl, dibenzoyl, alkanoyl, alkenoyl, benzoyl alkyl substituted alkanoyl, aryl, acyl, heterocylic, heteroraryl, and a derivative thereof; or wherein R4 is CH2R6, wherein R1 and R2 independently consists an 0-angeloyl group, or at least two of R1, R2 and R6 are 0-angeloyl; or at least one of R1, R2 or R6 is a sugar moiety substituted with two groups selecting from acetyl, angeloyl, tigloyl, senecioyl, dibenzoyl and benzoyl; or at least one of R1, R2 or R6 is a sugar moiety with two 0-angeloyls; or wherein R5 is/are the sugar moiety(ies) selected from the following sugars and alduronic acids: glucose, galactose, rhamnose, arabinose, xylose, fucose, allose, altrose, gulose, idose, lyxose, mannose, psicose, ribose, sorbose, tagatose, talose, fructose, glucuronic acid, galacturonic acid; or their derivatives thereof, or the combination thereof; wherein the sugar preferably comprises glucuronic acid, arabinose and galactose; or wherein R5 is/are sugar moiety(ies) selected from a group consisting of glucose, galactose, arabinose, alduronic acid, glucuronic acid, galacturonic acid, and a derivative or combination thereof; or wherein R5 is 3-β-O-{[(α-L-rhamnopyranosyl-(1→2)]-α-L-rhamnopyranosyl-(1→2)-β-D-galactopyranosyl-(1→3)]-[β-D-galactopyranosyl-(1→2)]-β-D-glucuronopyranosyl}, or 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosy(1→3)-β-D-glucuronopyranosy, or 3-O-[β-D-glucopyranosyl-(1→2)]-α-L-arabinofuranosy (1→3)-β-D-glucuronopyranosyl, or 3-O-[β-glucopyranosyl (1→2)]-β-arabinofuranosyl (1→4)-β-glucuronopyranosyl, or 3-O-[β-D-galactopyranosyl(1→2)]-β-D-xylopyranosyl (1→3)-β-D-glucuronopyranosyl.

### Claim 144 (depends on 143)

The compound of claim 143, wherein R1 and R2 of the compound is individually selected from O-angeloyl, 0-tigloyl, O-senecioyl, and O-benzoyl, or at least one of R1 and R2 is a sugar moiety, wherein the sugar moiety having two groups selecting from acetyl, angeloyl, tigloyl, senecioyl, dibenzoyl, benzoyl; R5 is a hydrogen or sugar moiety(ies), wherein the sugar moiety(ies) is/are selected from a group of glucose, galactose, arabinose and derivatives thereof, wherein the derivatives are acid, ester and salt.

### Claim 145 (depends on 143)

The compound of claim 143, wherein the modulating secretion or expression of adhesion proteins of cell, wherein the adhesion proteins comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, polyglycans, cadherin, heparin, tenascin, CD 54 and CAM, ITGAV, TNC, COL1A1, FN1, LAMA4, family protein relate to potassium channel, RAB3B, thrombospondin, insulin-like growth factor, G-protein and Glypican.

### Claim 146 (depends on 143)

The compound of claim 143, wherein the modulating the secretion or expression of adhesion protein comprises reducing the secretion or expression of fibronectin for inhibiting the metastasis or growth of cancer cells, wherein the cancer is selected from breast, leukocyte, liver, ovarian, bladder, prostate, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervix, esophagus, testis, spleen, kidney, lymph, pancreas, stomach and thyroid cancer.

### Claim 147 (depends on 143)

The compound of claim 143, wherein the modulating secretion or expression of angiopoietin comprising angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6 and angiopoietin-like 7.

### Claim 148 (depends on 143)

The compound of claim 143, wherein the modulating secretion or expression of angiopoietin comprises positive and negative regulating; wherein modulating angiopoietin comprises stimulating secretion or expression of the angiopoietin 2 in order to inhibit angiogenesis; or wherein modulating angiopoietin comprises inhibiting secretion or expression of the angiopoietin 1 in order to inhibit angiogenesis.

### Claim 149 (depends on 143)

The compound of claim 143, wherein the method includes increasing the expression of the protein phosphatase 1, dual specificity phosphatase 10; or increasing expression of the genes of ANGPT2, DDIT3, LIF and NFKB1Z.

### Claim 150 (depends on 143)

The compound of claim 143, wherein the compound is selected from the following:
a) An isolated, purified or synthesized compound having structure Xanifolia(Y),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosy(1→3)-β-D-glucuronopyranosyl-21,22-O-diangeloyl-3β, 15α, 16α, 21β, 22α, 28-hexahydroxyolean-12-ene;
b) An isolated, purified or synthesized compound having structure Xanifolia (Y1),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosyl(1→3)-β-D-glucuronopyranosyl-21-O-(3,4-diangeloyl)-α-L-rhamnophyranosyl-22-O-acetyl-3β,16α, 21β, 22α, 28-pentahydroxyolean-12-ene;
c) An isolated, purified or synthesized compound having structure Xanifolia (Y2),
or chemical name: 3-O-[β-D-glucopyranosyl-(1→2)]-α-L-arabinofuranosy(1→3)-β-D-glucuronopyranosyl-21,22-O-diangeloyl-3β, 15α, 16α, 21β, 22α, 24β, 28-heptahydroxyolean-12-ene;
d) An isolated, purified or synthesized compound having structure Xanifolia (Y8),
or chemical name: 3-O-[β-glucopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21, 22-O-diangeloyl-3β, 16α, 21β, 22α, 24β, 28-hexahydroxyolean-12-ene;
e) An isolated, purified or synthesized compound having structure Xanifolia (Y9),
or chemical name: 3-O-[β-galactopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21-O-(3, 4-diangeloyl)-α-rhamnopyranosyl-28-O-acetyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene; and
f) An isolated, purified or synthesized compound having structure Xanifolia (Y10),
or chemical name: 3-O-[β-galactopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21, 22-O-diangeloyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene.
g) An isolated, purified or synthesized compound having structure Xanifolia(Y0),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosyl(1→3)-β-D-glucuronopyranosyl-21-O-angeloyl, 22-O-(2-methylpropanoyl)-3β,15α, 16α,21β, 22α, 28-hexahydroxyolean-12-ene,
h) An isolated, purified or synthesized compound having structure Xanifolia(X),
or chemical name: 3-O-{[β-D-galactopyranosyl (1→2)]-[α-L-arabinofuranosyl(1→3)]-β-D-glucuronopyranoside butyl ester}-21-O-acetyl-22-O-angeloyl-3β,16α,21β,22α,28-pentahydroxyolean-12-ene.
i) An isolated, purified or synthesized compound having structure (Y7),
or chemical name: 3-O-[β-D-galactopyranosyl-(1→2)]-α-L-arabinofuranosyl-(1→3)-β-D-glucuronopyranosyl-21-O-angeloyl-28-O-2-methylbutanoyl-3β, 15α, 16α, 21β, 22α, 28-hexahydroxyolean-12-ene
j) An isolated, purified or synthesized compound having structure (ACH-Y):
k) An isolated, purified or synthesized compound having structure:
or chemical name: 3-O-[β-glucopyranosyl (1→2)]-β-arabinofuranosyl (1→4)-β-glucuronopyranosyl-21-O-angeloyl-22-O-acteyl-3β, 16α, 21β, 22α, 24β, 28-hexahydroxyolean-12-ene;
(l) An isolated, purified or synthesized compound having structure(Y5):
(m) An isolated, purified or synthesized compound having structure:
wherein R1 and R2 are O(C═O)C(CH3)=CH(CH3), R3 is OH, and R4 is OH;
(n) An isolated, purified or synthesized compound having structure(ACH-Mb5):
(o) An isolated, purified or synthesized compound having structure(Mb12):
wherein R1 is O(C═O)C(CH3)=CH(CH3), R2 is O(C═O)CH═CH—C6H5, R3 and R4 are OH, R6, R7, R8, R9, R10, R11 and R12 are CH3, and R13 is COOCH3, also named Mb12;
(p) An isolated, purified or synthesized compound having structure(Ba 1):
3-O-[β-D-galactopyranosyl(1→2)]-β-D-xylopyranosyl (1→3)-β-D-glucuronopyranosyl-21-O-angeloyl, 22-O-angeloyl-3β, 15α, 21β, 22α, 28-pentahydroxyolean-12-ene, named Ba 1;
(r) An isolated, purified or synthesized compound having structure(Z12):
3-O-[β-D-galactopyranosyl(1→2)]-β-D-xylopyranosyl (1→3)-β-D-glucuronopyranosyl-21-O-angeloyl, 22-O-tigloyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene;

### Claim 151 (depends on 143)

The compound of claim 143, wherein the compound is selected from the following:
a) An isolated, purified or synthesized compound having structure ((ACH-Y)):
b) An isolated, purified or synthesized compound having structure (ACH-Z4):
c) An isolated, purified or synthesized compound having structure (ACH-Y10):
d) An isolated, purified or synthesized compound having structure (ACH-Y2):
e) An isolated, purified or synthesized compound having structure (ACH-Y8):
f) An isolated, purified or synthesized compound having structure (ACH-Y7):
h) An isolated, purified or synthesized compound having structure (ACH-Y0):
i) An isolated, purified or synthesized compound having structure (ACH-E):
j) An isolated, purified or synthesized compound having structure (ACH-X):
k) An isolated, purified or synthesized compound having structure (ACH-Mb5):
l) An isolated, purified or synthesized compound having structure (ACH-Mb12):

### Claim 152

A method for modulating the secretion or expression of adhesion proteins or angiopoietins of cells, for inhibiting the metastasis of cancer cell in a subject, comprising contacting said subject with an effective amount of an isolated, purified or synthesized compound, or its salt, or ester thereof, selected from the formula:
also named (1E), wherein
R1 is selected from hydrogen, hydroxyl, O-angeloyl, 0-tigloyl, O-senecioyl, O-alkyl, O-dibenzoyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-benzoyl alkyl substituted O-alkanoyl, O-alkanoyl substituted with phenyl, O-alkenoyl substituted with phenyl, O-aryl, O-acyl, O-heterocylic, O-heteroraryl, and derivatives thereof;
R2 is selected from hydrogen, hydroxyl, O-angeloyl, 0-tigloyl, O-senecioyl, O-alkyl, O-dibenzoyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-benzoyl alkyl substituted O-alkanoyl, O-alkanoyl substituted phenyl, O-alkenoyl substituted phenyl, O-aryl, O-acyl, O-heterocylic, O-heteroraryl, and derivatives thereof;
R4 represents CH3, CHO, CH2R6 or CORE, wherein R6 is selected from hydroxyl, O-angeloyl, O-tigloyl, O-senecioyl, O-alkyl, O-dibenzoyl, O-benzoyl, O-alkanoyl, O-alkenoyl, 0-benzoyl alkyl substituted O-alkanoyl, O-alkanoyl substituted phenyl, O-alkenoyl substituted phenyl, O-aryl, O-acyl, O-heterocylic, O-heteroraryl, and derivatives thereof; R3 is H or OH; R8 is H or OH;
R16 is H, or R4 and R16 may form an oxygen bridge with divalent radical formula of —CH2-O—, CH(OH)—O— or C(═O)—O—wherein the —O-may be replaced with —NH—; wherein when the C12-13 of ring 3 of the triterpene has a double bond then R16 is absent;
R5 is a hydrogen, heterocyclic or sugar moiety(ies), wherein the sugar moiety(ies) is/are selected from a group consisting of glucose, galactose, rhamnose, arabinose, xylose, fucose, allose, altrose, gulose, idose, lyxose, mannose, psicose, ribose, sorbose, tagatose, talose, fructose, alduronic acid, glucuronic acid, galacturonic acid, and derivatives or combination thereof; wherein R9, R10, R11, R12, R13, R14, R15 are independently attached a group selecting from CH3, CH2OH, CHO, COOH, COO-alkyl, COO-aryl, COO-heterocyclic, COO-heteroaryl, CH2Oaryl, CH2O-heterocyclic, CH2O-heteroaryl, alkyls group, hydroxyl, acetyl group, particularly CH3; wherein at least two of R1, R2 and R6 are comprising a group selected from O-angeloyl, O-tigloyl, O-senecioyl, O-dibenzoyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-benzoyl alkyl substituted O-alkanoyl, O-aryl, O-acyl, O-heterocylic, O-heteroraryl, and derivatives thereof; or at least one of R1, R2, and R4 is a sugar moiety substituted with at least two groups selected from a group consisting of angeloyl, acetyl, tigloyl, senecioyl, benzoyl, dibenzoyl, alkanoyl, alkenoyl, benzoyl alkyl substituted alkanoyl, aryl, acyl, heterocylic, heteroraryl, and a derivative thereof; or wherein R4 is CH2R6, wherein R1 and R2 independently consists an O-angeloyl group, or at least two of R1, R2 and R6 are O-angeloyl; or at least one of R1, R2 or R6 is a sugar moiety substituted with two groups selecting from acetyl, angeloyl, tigloyl, senecioyl, dibenzoyl and benzoyl; or at least one of R1, R2 or R6 is a sugar moiety with two O-angeloyls; or wherein R5 is/are the sugar moiety(ies) selected from the following sugars and alduronic acids: glucose, galactose, rhamnose, arabinose, xylose, fucose, allose, altrose, gulose, idose, lyxose, fructose, glucuronic acid, galacturonic acid; or their derivatives thereof, or the combination thereof; wherein the sugar preferably comprises glucuronic acid, arabinose and galactose; or wherein R5 is/are sugar moiety(ies) selected from a group consisting of glucose, galactose, arabinose, alduronic acid, glucuronic acid, galacturonic acid, and a derivative or combination thereof; or wherein R5 is 3-β-O-{[(α-L-rhamnopyranosyl-(1→2)]-α-L-rhamnopyranosyl-(1→2)-β-D-galactopyranosyl-(1→3)]-[β-D-galactopyranosyl-(1→2)]-β-D-glucuronopyranosyl), or 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosy(1→3)-β-D-glucuronopyranosy, or 3-O-[β-D-glucopyranosyl-(1→2)]-α-L-arabinofuranosy (1→3)-β-D-glucuronopyranosyl, or 3-O-[β-glucopyranosyl (1→2)]-fl-arabinofuranosyl (1→4)-β-glucuronopyranosyl, or 3-O-[β-D-galactopyranosyl(1→2)]-β-D-xylopyranosyl (1→3)-β-D-glucuronopyranosyl.

### Claim 153 (depends on 152)

The method of claim 152, wherein R1 and R2 of the compound is individually selected from O-angeloyl, O-tigloyl, 0-senecioyl, and O-benzoyl, or at least one of R1 and R2 is a sugar moiety, wherein the sugar moiety having two groups selecting from acetyl, angeloyl, tigloyl, senecioyl, dibenzoyl, benzoyl; R5 is a hydrogen or sugar moiety(ies), wherein the sugar moiety(ies) is/are selected from a group of glucose, galactose, arabinose and derivatives thereof, wherein the derivatives are acid, ester and salt.

### Claim 154 (depends on 152)

The method of claim 152, wherein the modulating secretion or expression of adhesion proteins of cell, wherein the adhesion proteins comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, polyglycans, cadherin, heparin, tenascin, CD 54 and CAM, ITGAV, TNC, COL1A1, FN1, LAMA4, family protein relate to potassium channel, RAB3B, thrombospondin, insulin-like growth factor, G-protein and Glypican.

### Claim 155 (depends on 152)

The method of claim 152, wherein the modulating the secretion or expression of adhesion protein comprises reducing the secretion or expression of fibronectin for inhibiting the metastasis or growth of cancer cells, wherein the cancer is selected from breast, leukocyte, liver, ovarian, bladder, prostate, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervix, esophagus, testis, spleen, kidney, lymph, pancreas, stomach and thyroid cancer.

### Claim 156 (depends on 152)

The method of claim 152, wherein the modulating secretion or expression of angiopoietin comprising angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6 and angiopoietin-like 7.

### Claim 157 (depends on 152)

The method of claim 152, wherein the modulating secretion or expression of angiopoietin comprises positive and negative regulating; wherein modulating angiopoietin comprises stimulating secretion or expression of the angiopoietin 2 in order to inhibit angiogenesis; or wherein modulating angiopoietin comprises inhibiting secretion or expression of the angiopoietin 1 in order to inhibit angiogenesis

### Claim 158 (depends on 152)

The method of claim 152, wherein the method includes increasing the expression of the protein phosphatase 1, dual specificity phosphatase 10; or increasing expression of the genes of ANGPT2, DDIT3, LIF and NFKB1Z.

### Claim 159 (depends on 152)

The method of claim 152, wherein the compound is selected from the following:
a) An isolated, purified or synthesized compound having structure Xanifolia(Y),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosy(1→3)-β-D-glucuronopyranosyl-21,22-O-diangeloyl-3β,15α, 16α,21β,22α,28-hexahydroxyolean-12-ene;
b) An isolated, purified or synthesized compound having structure Xanifolia (Y1),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosyl(1→3)-β-D-glucuronopyranosyl-21-O-(3,4-diangeloyl)-α-L-rhamnophyranosyl-22-O-acetyl-3β,16α,21β,22α,28-pentahydroxyolean-12-ene;
c) An isolated, purified or synthesized compound having structure Xanifolia (Y2),
or chemical name: 3-O-[β-D-glucopyranosyl-(1→2)]-α-L-arabinofuranosy(1→3)-β-D-glucuronopyranosyl-21,22-O-diangeloyl-3β, 15α, 16α, 21β, 22α, 24β, 28-heptahydroxyolean-12-ene;
d) An isolated, purified or synthesized compound having structure Xanifolia (Y8),
or chemical name: 3-O-[β-glucopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21, 22-O-diangeloyl-3β, 16α, 21β, 22α, 24β, 28-hexahydroxyolean-12-ene;
e) An isolated, purified or synthesized compound having structure Xanifolia (Y9),
or chemical name: 3-O-[β-galactopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21-O-(3, 4-diangeloyl)-α-rhamnopyranosyl-28-O-acetyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene; and
f) An isolated, purified or synthesized compound having structure Xanifolia (Y10),
or chemical name: 3-O-[β-galactopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21, 22-O-diangeloyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene.
g) An isolated, purified or synthesized compound having structure Xanifolia(Y0),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosyl(1→3)-β-D-glucuronopyranosyl-21-O-angeloyl, 22-O-(2-methylpropanoyl)-3β,15α, 16α,21β, 22α, 28-hexahydroxyolean-12-ene,
h) An isolated, purified or synthesized compound having structure Xanifolia(X),
or chemical name: 3-O-{[β-D-galactopyranosyl (1→2)]-[α-L-arabinofuranosyl(1→3)]-β-D-glucuronopyranoside butyl ester}-21-O-acetyl-22-O-angeloyl-3β,16α,21β,22α,28-pentahydroxyolean-12-ene.
i) An isolated, purified or synthesized compound having structure (Y7),
or chemical name: 3-O-[β-D-galactopyranosyl-(1→2)]-α-L-arabinofuranosyl-(1→3)-β-D-glucuronopyranosyl-21-O-angeloyl-28-O-2-methylbutanoyl-3β, 15α, 16α, 21β, 22α, 28-hexahydroxyolean-12-ene
j) An isolated, purified or synthesized compound having structure (ACH-Y):
k) An isolated, purified or synthesized compound having structure:
or chemical name: 3-O-[β-glucuronopyranosyl-(1→2)]-βarabinofuranosyl (1→4)-β-glucuronopyranosyl-21-O-angeloyl-22-O-acteyl-3β, 16α, 21β, 22α, 24β, 28-hexahydroxyolean-12-ene;
(l) An isolated, purified or synthesized compound having structure(Y5):
(m) An isolated, purified or synthesized compound having structure:
wherein R1 and R2 are O(C═O)C(CH3)=CH(CH3), R3 is OH, and R4 is OH
(n) An isolated, purified or synthesized compound having structure(ACH-Mb5):
(o) An isolated, purified or synthesized compound having structure(Mb12):
wherein R1 is O(C═O)C(CH3)=CH(CH3), R2 is O(C═O)CH═CH—C6H5, R3 and R4 are OH, R6, R7, R8, R9, R10, R11 and R12 are CH3, and R13 is COOCH3, also named Mb12;
(p) An isolated, purified or synthesized compound having structure(Ba 1):
3-O-[β-D-galactopyranosyl(1→2)]-β-D-xylopyranosyl (1→3)-β-D-glucuronopyranosyl-21-O-angeloyl,22-O-angeloyl-3β, 15α, 21β, 22α, 28-pentahydroxyolean-12-ene, named Ba 1;
(r) An isolated, purified or synthesized compound having structure (Z12):
3-O-[β-D-galactopyranosyl(1→2)]-β-D-xylopyranosyl (1→3)-β-D-glucuronopyranosyl-21-O-angeloyl, 22-O-tigloyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene;

### Claim 160 (depends on 152)

The method of claim 152, wherein the compound is selected from the following:
a) An isolated, purified or synthesized compound having structure ((ACH-Y)):
b) An isolated, purified or synthesized compound having structure (ACH-Z4):
c) An isolated, purified or synthesized compound having structure (ACH-Y10):
d) An isolated, purified or synthesized compound having structure (ACH-Y2):
e) An isolated, purified or synthesized compound having structure (ACH-Y8):
f) An isolated, purified or synthesized compound having structure (ACH-Y7):
h) An isolated, purified or synthesized compound having structure (ACH-Y0):
i) An isolated, purified or synthesized compound having structure (ACH-E):
j) An isolated, purified or synthesized compound having structure (ACH-X):
k) An isolated, purified or synthesized compound having structure (ACH-Mb5):
l) An isolated, purified or synthesized compound having structure (ACH-Mb12):

### Claim 161

A method for treating parasites in a subject, comprising contacting said subject with an effective amount of an isolated, purified or synthesized compound, or its salt, or ester thereof, selected from following:
a) An isolated, purified or synthesized compound having structure Xanifolia(Y),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosy(1→3)-β-D-glucuronopyranosyl-21,22-O-diangeloyl-3β, 15α, 16α, 21β, 22α, 28-hexahydroxyolean-12-ene;
b) An isolated, purified or synthesized compound having structure Xanifolia (Y1),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosyl(1→3)-β-D-glucuronopyranosyl-21-O-(3,4-diangeloyl)-α-L-rhamnophyranosyl-22-O-acetyl-3β,16α, 21β, 22α, 28-pentahydroxyolean-12-ene;
c) An isolated, purified or synthesized compound having structure Xanifolia (Y2),
or chemical name: 3-O-[β-D-glucopyranosyl-(1→2)]-α-L-arabinofuranosy(1→3)-β-D-glucuronopyranosyl-21,22-O-diangeloyl-3β, 15α, 16α, 21β, 22α, 24β, 28-heptahydroxyolean-12-ene;
d) An isolated, purified or synthesized compound having structure Xanifolia (Y8),
or chemical name: 3-O-[β-glucopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21, 22-O-diangeloyl-3β, 16α, 21β, 22α, 24β, 28-hexahydroxyolean-12-ene;
e) An isolated, purified or synthesized compound having structure Xanifolia (Y9),)
or chemical name: 3-O-[β-galactopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21-O-(3, 4-diangeloyl)-α-rhamnopyranosyl-28-O-acetyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene; and
f) An isolated, purified or synthesized compound having structure Xanifolia(Y10),
or chemical name: 3-O-[β-galactopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21, 22-O-diangeloyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene.
g) An isolated, purified or synthesized compound having structure Xanifolia(Y0),
or chemical name: 3-O-[β-D-galactopyranosyl(1→2)]-α-L-arabinofuranosyl(1→3)-β-D-glucuronopyranosyl-21-O-angeloyl,22-O-(2-methylpropanoyl)-3β,15α, 16α,21β, 22α, 28-hexahydroxyolean-12-ene,
h) An isolated, purified or synthesized compound having structure Xanifolia(X),
or chemical name: 3-O-{[β-D-galactopyranosyl (1→2)]-[α-L-arabinofuranosyl (1→3)]-β-D-glucuronopyranoside butyl ester}-21-O-acetyl-22-O-angeloyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene.
i) An isolated, purified or synthesized compound having structure (Y7),
or chemical name: 3-O-[β-D-galactopyranosyl-(1→2)]-α-L-arabinofuranosyl-(1→3)-β-D-glucuronopyranosyl-21-O-angeloyl-28-O-2-methylbutanoyl-3β, 15α, 16α, 21β, 22α, 28-hexahydroxyolean-12-ene
j) An isolated, purified or synthesized compound having structure (ACH-Y):
k) An isolated, purified or synthesized compound having structure:
or chemical name: 3-O-[β-glucopyranosyl (1→2)]-β-arabinofuranosyl (14)-β-glucuronopyranosyl-21-O-angeloyl-22-O-acteyl-3β, 16α, 21β, 22α, 24β, 28-hexahydroxyolean-12-ene;
(l) An isolated, purified or synthesized compound having structure (Y5):
(m) An isolated, purified or synthesized compound having structure:
wherein R1, R2, are O(C═O)C(CH3)=CH(CH3), R3 is OH, R4 is OH
(n) An isolated, purified or synthesized compound having structure(ACH-Mb5):
(o) An isolated, purified or synthesized compound having structure(Mb12):
wherein R1 is O(C═O)C(CH3)=CH(CH3), R2 is O(C═O)CH═CH—C6H5, R3, R4 are OH, R6, R7, R8, R9, R10, R11, R12 are CH3, R13 is COOCH3, also named Mb12;
(p) An isolated, purified or synthesized compound having structure(Ba 1):
3-O-[β-D-galactopyranosyl(1→2)]-β-D-xylopyranosyl (1→3)-β-D-glucuronopyranosyl-21-O-angeloyl,22-O-angeloyl-3β, 15α, 21β, 22α, 28-pentahydroxyolean-12-ene, named Ba 1;
(q) An isolated, purified or synthesized compound having structure(Z12):
3-O-[β-D-galactopyranosyl(1→2)]-β-D-xylopyranosyl (1→3)-β-D-glucuronopyranosyl-21-O-angeloyl, 22-O-tigloyl-3β, 16α, 21β, 22α, 28-pentahydroxyolean-12-ene;
r) An isolated, purified or synthesized compound having structure ((ACH-Y)):
s) An isolated, purified or synthesized compound having structure (ACH-Z4):
t) An isolated, purified or synthesized compound having structure (ACH-Y10):
u) An isolated, purified or synthesized compound having structure (ACH-Y2):
v) An isolated, purified or synthesized compound having structure (ACH-Y8):
w) An isolated, purified or synthesized compound having structure (ACH-Y7):
x) An isolated, purified or synthesized compound having structure (ACH-Y0):
y) An isolated, purified or synthesized compound having structure (ACH-E):
z) An isolated, purified or synthesized compound having structure (ACH-X):
z1) Anisolated, purified or synthesized compound having structure (ACH-Mb5):
z2) Anisolated, purified or synthesized compound having structure (ACH-Mb12):

### Claim 162 (depends on 143)

The compound of claim 143, wherein the compound for modulating the gene expression selected from: ABL2, ADAMTS1, AKR1C3, AMIGO2, ANGPT2, ANKRD11, AP2B1, APEH, APLP2, ARL10C, ARMCO, ARMCX1, ARMCX6, ARNTL2, ATF3, ATP6V0E, ATP6V1B2, ATP6V1C1, ATP6V1C1, BCL2A1, BCL6, BRI3, BTD, C14orf109, C14orf78, C17orf32, C6orf65, C9orf10, C9orf103, CAD, CAV1, CAV2, CBLL1, CCL20, CD33L3, CEBPB, CEP4, CFH///CFHL1, CHRDL1, CITED2, CLDN14, CLN8, CLIA, CNAP1, COG6, COL18A1, COL4A2, COL5A1, COL5A2, COL6A3, COPG, CPM, CPNE3, CPSF1, CSRP2BP, CSTB, CTNS, CXCL2, DDB1, DDIT3, DDX20, DKFZP564I1171, DKFZP586J0619, DUSP10, DUSP10, DYRK3, EEF2K, EFEMP1, EMP1, EVC, EVI2A, EXT2, FAM62A, FER1L3, FLJ14466, FLNA, FN1, GANAB, GDF15, GEM, GNPDA1, GPAA1, GPC6, GPNMB, GPNMB, GUSB, H2AFV, H2AFV, HDAC9, HDLBP, HECW2, HMGA2, HMOX1, HSDL2, HSPBAP1, HSPC196, HYOU1, IDS, IGFBP3, IKBKAP, INSIG1, IPO4, IRS2, JAG1, KDELR3, KIAA0251, KIAA0586, KIAAl211, KIAA1462, KIAA1706, KIAA1754, KRT18, KRT7, KRTAP4-7, LAMP2, LEPR, LEPREL1, LHFPL2, LIF, LOC286044, LOC339229, LOC90693, LRRC8E, MAFG, MAGED2, MCTP1, MGC16291, MGC19764, MGC5618, MRPS30, MRPS31, MTERFD3, MYH9, NAGA, NAV2, NCSTN, NEK9, NEU1, NFKBIZ, NMT2, NPC2, NSUN5C, NTNG1, NUP188, OACT2, OS9, P4HA1, P8, PALM2-AKAP2, PALM2-AKAP2, PARVA, PBX2, PDE4DIP, PDIA4, PDIA6, PEG10, PHF19, PIK4CA, PLEKHM1, PLOD1, PLOD2, PPP1R15A, PPP1R15A, PRKDC, PRSS23, PRSS23, PSEN2, PSMD1, PTPRF, PTPRJ, RAB32, RAB9A, RG9MTD1, RGS4, RHOQ, RND3, RNF25, RNPEP///UBE2V1///Kua///Kua-UEV, RNU17D, ROBO4, RRAGC, RRS1, SEC31L1, SERPINB2, SERPINB7, SESN2, SGEF, SGSH, SKIV2L, SLC25A21, SLC35A3, SLC3A2, SMARCA1, SNAPC1, SNF1LK, SPOCD1, SPTAN1, SQSTM1, ST3GAL6, STC2, STX3A, TFPI2, TGFBI, TGM2, THRAP1, TLN1, TMEM60, TNFAIP3, TRIB3, TRIO, TSC2, UAP1L1, UBAP2L, UPP1, URB, USP11, USPS, VDR, WDR4, YTHDF2, ZCCHC9, ZDHHC20, ZFHX1B, ZNF185, ZNF278, ZNF690, ZNF697, ITGAV, LAMA4, LAMB2, LAMC1, LAMB1, LAMA5, LAMC1, LAMA2, LAMB1, LAMA3, SCAMPI, TICAM2, CAMK2B, DL1, ICAM3, CEECAM1, ICAM5, CAMK1G, CAMSAP1, MCAM, CAMTA1, CKN1, ALCAM, DCAMKL 2, CEACAM3, CAMK2D, CAMK2B, SCAMPS, CAMK4, NCAM1, CAMK2G, MYH10, MYO1D, MYO5A, MYO1C, MYLK, MYO6, MYLC2PL, MYO10, BECN1, MYO1E, TPM3, M-RIP, MYO1B, MYL6, MYOHD1, BECN1, TPM4, MYLK, MYOHD1, LOC221875, LOC402643, MYO15B, LOC129285, MYH11, MYO9B, CTNNAL1, CDH13, CDH12, CTNNB1, CDH5, CTNND1, CDH2, PCDHB16, CTNNA1, CELSR2, PCDHB6, PCDHB7, CTNND2, PCDHGC3, PCDHGB4, PCDHGA8, PCDHGA12, PCDHGC5, PCDHGC4, PCDHGB7, PCDHGB6, PCDHGB5, PCDHGB3, PCDHGB2, PCDHGB1, PCDHGA11, PCDHGA10, PCDHGA9, PCDHGA7, PCDHGA6, PCDHGA5, PCDHGA4, PCDHGA3, PCDHGA2, PCDHGA1, CTNND1, CDH23, PCDHB12, PCDHB10, PCDH18, CDH2O, PCDH9, PCDHGA12, PCDHGA11, PCDHGA10, PCDHGA6, PCDHGA5, PCDHGA3, PCDH7, CDH18, CDH6, CCBE1, COL10A1, COL12A1, COL13A1, COL1A1, COL21A1, COL4A1, COL4A5, COL4A6, COL6A1, COL6A2, COL9A1, MMP9, P4HA1, P4HA2, P4HB, PCOLCE, PCOLCE2, PCOTH, PLOD3, CIB1, ILK, ITGA2, ITGA3, ITGA4, ITGA6, ITGAV, ITGB1, ITGB1BP1, ITGB2, ITGB5, ITGBL1, TNC, EMILIN1, ICAM1, HSPG2, HPSE, HS2ST1, SDC2.
